=>
Uploading C:\Program Files\Stnexp\Queries\10597828-amended.str



chain nodes :
11 13 14 15
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
4-11 11-13 11-14 14-15
ring bonds :
1-2 1-5 1-9 2-3 3-4 4-5 5-6 6-7 7-8 8-9
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 4-11 11-13 11-14 14-15
normalized bonds :
1-9 5-6 6-7 7-8 8-9
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:Atom
13:CLASS 14:CLASS 15:CLASS
Generic attributes :
11:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : Exactly 1
Type of Ring System : Monocyclic

Element Count :
Node 11: Limited
C,C4
S,S1

L1 STRUCTURE UPLOADED

=> d his

FILE 'REGISTRY' ENTERED AT 16:57:18 ON 05 NOV 2008
L1 STRUCTURE UPLOADED
L3 33 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 16:58:20 ON 05 NOV 2008
L4 4 S L3
L5 1 S US200!-597828/APPS

```
L6             1 S L4 AND L5
L7             3 S L4 NOT L5

     FILE 'REGISTRY' ENTERED AT 16:59:10 ON 05 NOV 2008
=> d l1
L1 HAS NO ANSWERS
L1              STR
```




```
=> fil caplus

=> d l6 bib abs

√L6   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2008 ACS on STN - INSTANT
PA   Glaxo Group Limited, UK
     PATENT NO.          KIND   DATE        √APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   WO 2005075465        A1    20050818    WO 2005-EP1432         20050207
     EP 1720864           A1    20061115    EP 2005-707356         20050207
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV
     JP 2007522142        T     20070809    JP 2006-551827         20050207
     US 20070149519       A1    20070628    US 2006-597828         20060809 <--
PRAI GB 2004-2809         A     20040209
     WO 2005-EP1432       W     20050207


=> d l7 tot bib abs hitstr

√L7   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2008 ACS on STN
SO   Bioorganic & Medicinal Chemistry Letters √ (2006), 16(24), 6236-6240


L7   ANSWER 2 OF 3  CAPLUS  COPYRIGHT 2008 ACS on STN
PA   Smithkline Beecham Corporation, USA
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------   --------
PI   WO 2005037827        A1    20050428    WO 2004-US33585        20041012
     EP 1685128           A1    20060802    EP 2004-794836         20041012
     JP 2007509070        T     20070412    JP 2006-535584         20041012
     US 20070060576       A1    20070315    √US 2006-575210         20060410
PRAI US 2003-511991P      P     20031016
     WO 2004-US33585      W     20041012
OS   CASREACT 142:430276; MARPAT 142:430276
GI
```



I



II

AB Title compds. [I; R1 = H, alkyl, alkenyl, alkynyl, COR7, CO2R7, cyano, (substituted) heterocyclyl, etc.; Q1 = (R2)a(Y1)b(R2)cR3; a, b, c, aa, bb, cc = 0, 1; ≥1 of, a, b = 1; n = 0-4; Q4 = (R2)aa(Y2)bb(R2)ccR4; Y1, Y2 = O, CO, CO2, OSO2, CONR7, etc.; R2 = alkylene, alkenylene, alkynylene; R3, R4 = H, halo, alkyl, alkenyl, alkynyl, COR7, CO2R7, NO2, cyano, N3, etc.; R5 = H, halo, alkyl, cycloalkyl, OR7, NHSO2R7, etc.; R7 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl], were prepared by treatment of the corresponding N-unsubstituted benzimidazoles with 2-chloro-3-oxo-2,3-dihydrothiophene-2-carboxylates (II; R10 = alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, protecting group) in the presence of base. Thus, benzimidazole in CHCl3 was treated with Me 2-chloro-3-oxo-2,3-dihydro-2-thiophenecarboxylate and NaHCO3 followed by stirring for 16 h to give Me 5-(1H-benzimidazol-1-yl)-3-hydroxy-2-thiophenecarboxylate.

IT 660868-54-2 660869-82-9
RL: PRPH (Prophetic)
(Process for preparing thienylbenzimidazoles from benzimidazoles and 2-chloro-3-oxo-2,3-dihydrothiophene-2-carboxylates.)

RN 660868-54-2 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(1H-benzimidazol-1-yl)-3-[(2-methylphenyl)methoxy]- (CA INDEX NAME)



RN 660869-82-9 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:143141 CAPLUS Full-text
DN 140:199325
TI Preparation of benzimidazolyl substituted thiophenes as Polo like kinases (PLK) inhibitors for treating cancer
IN Andrews, Clarence W., III; Cheung, Mui; Davis-Ward, Ronda G.; Drewry, David Harold; Emmitte, Kyle Allen; Hubbard, Robert Dale; Kuntz, Kevin W.; Linn, James Andrew; Mook, Robert Anthony; Smith, Gary Keith; Veal, James Marvin
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 235 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004014899	A1	20040219	WO 2003-US24272	20030804
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493908	A1	20040219	CA 2003-2493908	20030804
AU 2003265348	A1	20040225	AU 2003-265348	20030804
AU 2003265348	B2	20070816		
EP 1546137	A1	20050629	EP 2003-784888	20030804
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013160	A	20050712	BR 2003-13160	20030804
CN 1688576	A	20051026	CN 2003-823755	20030804
JP 2006505522	T	20060216	JP 2004-527723	20030804
NZ 538134	A	20060331	NZ 2003-538134	20030804
RU 2296758	C2	20070410	RU 2005-102390	20030804
ZA 2005000864	A	20060426	ZA 2005-864	20050128
NO 2005000525	A	20050506	NO 2005-525	20050131
US 20060074119	A1	20060406	US 2005-522958	20050131
MX 2005PA01544	A	20050419	MX 2005-PA1544	20050208

	IN 2005KN00321	A	20060106	IN 2005-KN321	20050302
	US 20080269298	A1	20081030	US 2008-113224	20080501
PRAI	US 2002-402008P	P	20020808		
	WO 2003-US24272	W	20030804		
	US 2005-522958	A1	20050131		

OS MARPAT 140:199325

GI



I



II

AB The title compds. [I; R1 = H, alkyl, COR7, CO2R7, etc.; Q1 = OCH2Ph, NHCH2Ph (both substituted on Ph ring), etc.; n = 0-4; Q2 = OMe, Cl, Br, etc.; R5 = H, halo, alkyl, etc.; R7 = H, alkyl, cycloalkyl, etc.], useful for treating a condition mediated by PLK, were prepared E.g., a multi-step synthesis of II which showed pIC50 of > 7 in assay for inhibition of PLK1, was given. The pharmaceutical composition comprising the title compds. I is claimed.

IT 660869-82-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of benzimidazolylthiophenes as Polo like kinases (PLK) inhibitors)

RN 660869-82-9 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)



IT 660868-54-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzimidazolylthiophenes as Polo like kinases (PLK) inhibitors)

RN 660868-54-2 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(1H-benzimidazol-1-yl)-3-[(2-methylphenyl)methoxy]- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	19.74	203.95

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.20	-3.20

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:59:54 ON 05 NOV 2008